IN SILICO VALIDATION OF ANTI-RUSSELL’S VIPER VENOM ACTIVITY IN PHYLLANTHUS EMBLICA L. AND TAMARINDUS INDICA L.
Abstract
To validate the efficacy of viper anti-venom activity, a total of 79 phytochemicals from Phyllanthus emblica and 59 phytochemicals from Tamarindus indica were docked against each of the nine selected viper venom proteins such as basic phospholipase A2 VRV-PL-VIIIa, anticoagulant class II phospholipase A2, acidic phospholipase A2 Drk-a1, neutral phospholipase A2 RVV-PFIIc, L-amino acid oxidase, Russell's viper venom serine proteinase, RVV-V, cytotoxin drCT-1, dabocetin alpha subunit and cysteine-rich secretory protein Dr-CRPK using the tool Autodock. The structure of three proteins viz basic phospholipase A2 VRV-PL-VIIIa (PDB id-1OXL), anticoagulant class II phospholipase A2 (PDB id- 1VIP) and Russell's viper venom serine proteinase RVV-V (PDB id- 3S9A) were downloaded from RCSB Protein Data Bank and remaining targets 3D structures except neutral phospholipase A2 RVV-PFIIc were modelled using the tool SWISS-MODEL. The templates for modelling the structures were selected through BLASTp analysis. The structure of the neutral PLA2 was modelled using the tool I-TASSER. The stability of all the modelled structures were confirmed by Ramachandran Plot and the active site were detected using the tool MetaPocket2. The docked results revealed that both plants contain several inhibitory molecules against all the target proteins and certain compounds such as stigmasterol, β-sitosterol and campesterol, were present in both plants and each of these molecule can inhibit all venom proteins. The overall results substantiate the traditional use of these plants as antidote to snake bites. However, in vitro and in vivo experimental demonstration is essential for practical application of forgoing findings.
Keywords:
Russell’s viper, Docking, In silico screening, Phyllanthus emblica, Tamarindus indica.DOI
https://doi.org/10.25004/IJPSDR.2018.100403References
http://www. who.int/neglected_diseases/ diseases/en/ accessed on 03/10/2017.
Mohapatra B, Warrell DA, Suraweera W, Bhatia P, Dhingra N, Jotkar RM, Rodriguez PS, Mishra K, Whitaker R, Jha P. Million Death Study Collaborators. Snakebite mortality in India: A nationally representative mortality survey. PLoS Neglected Tropical Diseases. 2011; 5(4):e1018.
Antonypillai CN, Wass JA, Warrell DA, Rajaratnam HN. Hypopituitarism following envenoming by Russell’s vipers (Daboia siamensis and D. russelii) resembling Sheehan’s syndrome: First case report from Sri Lanka, a review of the literature and recommendations for endocrine management. QJM: An International Journal of Medicine. 2010; 104:97-108.
Warrell DA. Clinical toxicology of Snake bites in Asia. In: White MA, ed. Handbook of clinical toxicology of animal venoms and poisons. CRC Press, 1995.
Warrell DA. Snake venoms in science and clinical medicine. 1. Russell's viper: Biology, venom and treatment of bites. Trans R Soc Trop Med Hyg. 1989; 83:732-740.
Nisha NC, Sreekumar S, Biju CK, Krishnan PN. Snake antivenom: Virtual screening of plant-derived molecules. Biobytes. 2010; 6:14-22.
Kang TS, Georgieva D, Genov N, Murakami MT, Sinha M, Kumar RP, Kaur P, Kumar S, Dey S, Sharma S, Vrielink A. Enzymatic toxins from snake venom: Structural characterization and mechanism of catalysis. FEBS J. 2011; 278(23):4544-4576.
Nisha NC, Sreekumar S, Biju CK, Krishnan PN. Identification of lead compounds with cobra venom neutralising activity in three Indian medicinal plants. Int J Pharm Pharm Sci. 2014; 6: 536-541.
Alam MI, Gomes A. Snake venom neutralization by Indian medicinal plants (Vitex negundo and Emblica officinalis) root extracts. J Ethnopharmacol. 2003; 86:75-80.
Ushanandini S, Nagaraju S, Harish Kumar K, Vedavathi M, Machiah DK, Kemparaju K, Vishwanath BS, Gowda TV, Girish KS. The anti‐snake venom properties of Tamarindus indica Leguminosae) seed extract. Phytother. Res. 2006; 20:851-858.
Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL Workspace: A web-based environment for protein structure homology modelling. Bioinformatics. 2006; 22:195-201.
Ramachandran GN, Sasisekharan V. Conformation of polypeptides and proteins. Vol. 23, Adv Protein Chem.1968, pp.283-438.
Roy A, Kucukural A, Zhang Y. I-TASSER: A unified platform for automated protein structure and function prediction. Nature Protocols. 2010; 5(4):725-738.
Deepa V, Sreekumar S, Biju CK. Validation of Russell’s Viper Venom Detoxification Activity of Azadirachta indica through In silico Method. IOSR J Pharm Biol Sci. 2016; 11:35-46.
Warrell DA. Snake venoms in science and clinical medicine. Russell’s viper: Biology, venom and treatment of bites. Trans. R. Soc. Trop. Med. Hyg. 1989; 83(6):732-740.
WHO. Guidelines for the management of snakebites. New Delhi, India, 2016.
Kang TS, Georgieva D, Genov N, Murakami MT, Sinha M, Kumar RP, Kaur P, Kumar S, Dey S, Sharma S, Vrielink A. Enzymatic toxins from snake venom: Structural characterization and mechanism of catalysis. FEBS J. 2011; 278(23):4544-4576.
Fatima L, Fatah C. Pathophysiological and Pharmacological Effects of Snake Venom Components: Molecular Targets. J Clin Toxicol. 2014; 4(190):2161-0495.
Jayanthi GP, Gowda TV. Geographical variation in India in the composition and lethal potency of Russell’s Viper (Vipera russelli) venom. Toxicon. 1988; 26(3):257-64.
Saikia D, Majumdar S, Mukherjee AK. Mechanism of in vivo anticoagulant and haemolytic activity by a neutral phospholipase A2 purified from Daboia russelii venom: Correlation with clinical manifestations in Russell’s Viper envenomed patients. Toxicon. 2013; 76:291-300.
Izidoro LF, Sobrinho JC, Mendes MM, Costa TR, Grabner AN, Rodrigues VM, da Silva SL, Zanchi FB, Zuliani JP, Fernandes CFC, Calderon LA, Stábeli RG, Soares AM. Snake Venom L-Amino Acid Oxidases: Trends in Pharmacology and Biochemistry, Biomed Res Int. 2014; 2014:196-754.
Ogawa T, Chijiwa T, Oda-Ueda N, Ohno M. Molecular diversity and accelerated evolution of C-type lectin-like proteins from snake venom. Toxicon. 2005; 45(1):1-14.
Zhong SR, Jin Y, Wu JB, Chen RQ, Jia YH, Wang WY, Xiong YL, Zhang Y. Characterization and molecular cloning of dabocetin, a potent antiplatelet C-type lectin-like protein from Daboia russellii siamensis venom. Toxicon. 2006; 47(1):104-112.
Yamazaki Y, Morita T. Structure and function of snake venom cysteine-rich secretory proteins. Toxicon. 2004; 44(3):227-31.
Wang J, Shen B, Guo M, Lou X, Duan Y, Cheng XP, Teng M, Niu L, Liu Q, Huang Q, Hao Q. Blocking effect and crystal structure of natrin toxin, a cysteine-rich secretory protein from Naja atra venom that targets the BKCa channel. Biochemistry. 2005; 44(30):10145-52.
Guo M, Teng M, Niu L, Liu Q, Huang Q, Hao Q. Crystal structure of the cysteine-rich secretory protein stecrisp reveals that the cysteine-rich domain has a K+ channel inhibitor-like fold. J. Biol. Chem. 2005; 280(13):12405-12412.
Bickerton GR, Paolini GV, Besnard J, Muresan S, Hopkins AL. Quantifying the chemical beauty of drugs. Nature Chemistry. 2012; 4(2):90.
Nisha NC, Sreekumar S, Biju CK. Identification of lead compounds with cobra venom detoxification activity in Andrographis paniculata (burm. F.) Nees through in silico method. Int J Pharma Pharm Sci. 2016; 8: 7:212-217.
Lu J-J, Pan W, Hu YJ, Wang YT. Multi-Target Drugs: The Trend of Drug Research and Development. PLoS ONE. 2012; 7:6:e40262.
Published
Abstract Display: 640 
PDF Downloads: 687 
